Cargando…
Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial
Whether initiation of antiretroviral therapy (ART) regimens aimed at achieving greater concentrations within gut associated lymphoid tissue (GALT) impacts the level of mucosal immune reconstitution, inflammatory markers and the viral reservoir remains unknown. We included 12 HIV- controls and 32 ART...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721954/ https://www.ncbi.nlm.nih.gov/pubmed/26795282 http://dx.doi.org/10.1371/journal.ppat.1005381 |
_version_ | 1782411302230032384 |
---|---|
author | Serrano-Villar, Sergio Sainz, Talia Ma, Zhong-Min Utay, Netanya S. Wook-Chun, Tae Mann, Surinder Kashuba, Angela D. Siewe, Basile Albanese, Anthony Troia-Cancio, Paolo Sinclair, Elizabeth Somasunderam, Anoma Yotter, Tammy Deeks, Steven G. Landay, Alan Pollard, Richard B. Miller, Christopher J. Moreno, Santiago Asmuth, David M. |
author_facet | Serrano-Villar, Sergio Sainz, Talia Ma, Zhong-Min Utay, Netanya S. Wook-Chun, Tae Mann, Surinder Kashuba, Angela D. Siewe, Basile Albanese, Anthony Troia-Cancio, Paolo Sinclair, Elizabeth Somasunderam, Anoma Yotter, Tammy Deeks, Steven G. Landay, Alan Pollard, Richard B. Miller, Christopher J. Moreno, Santiago Asmuth, David M. |
author_sort | Serrano-Villar, Sergio |
collection | PubMed |
description | Whether initiation of antiretroviral therapy (ART) regimens aimed at achieving greater concentrations within gut associated lymphoid tissue (GALT) impacts the level of mucosal immune reconstitution, inflammatory markers and the viral reservoir remains unknown. We included 12 HIV- controls and 32 ART-naïve HIV patients who were randomized to efavirenz, maraviroc or maraviroc+raltegravir, each with fixed-dose tenofovir disoproxil fumarate/emtricitabine. Rectal and duodenal biopsies were obtained at baseline and at 9 months of ART. We performed a comprehensive assay of T-cell subsets by flow cytometry, T-cell density in intestinal biopsies, plasma and tissue concentrations of antiretroviral drugs by high-performance liquid chromatography/mass spectroscopy, and plasma interleukin-6 (IL-6), lipoteichoic acid (LTA), soluble CD14 (sCD14) and zonulin-1 each measured by ELISA. Total cell-associated HIV DNA was measured in PBMC and rectal and duodenal mononuclear cells. Twenty-six HIV-infected patients completed the follow-up. In the duodenum, the quadruple regimen resulted in greater CD8(+) T-cell density decline, greater normalization of mucosal CCR5(+)CD4(+) T-cells and increase of the naïve/memory CD8(+) T-cell ratio, and a greater decline of sCD14 levels and duodenal HIV DNA levels (P = 0.004 and P = 0.067, respectively), with no changes in HIV RNA in plasma or tissue. Maraviroc showed the highest drug distribution to the gut tissue, and duodenal concentrations correlated well with other T-cell markers in duodenum, i.e., the CD4/CD8 ratio, %CD4(+) and %CD8(+) HLA-DR(+)CD38(+) T-cells. Maraviroc use elicited greater activation of the mucosal naïve CD8(+) T-cell subset, ameliorated the distribution of the CD8(+) T-cell maturational subsets and induced higher improvement of zonulin-1 levels. These data suggest that combined CCR5 and integrase inhibitor based combination therapy in ART treatment naïve patients might more effectively reconstitute duodenal immunity, decrease inflammatory markers and impact on HIV persistence by cell-dependent mechanisms, and show unique effects of MVC in duodenal immunity driven by higher drug tissue penetration and possibly by class-dependent effects. |
format | Online Article Text |
id | pubmed-4721954 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-47219542016-01-30 Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial Serrano-Villar, Sergio Sainz, Talia Ma, Zhong-Min Utay, Netanya S. Wook-Chun, Tae Mann, Surinder Kashuba, Angela D. Siewe, Basile Albanese, Anthony Troia-Cancio, Paolo Sinclair, Elizabeth Somasunderam, Anoma Yotter, Tammy Deeks, Steven G. Landay, Alan Pollard, Richard B. Miller, Christopher J. Moreno, Santiago Asmuth, David M. PLoS Pathog Research Article Whether initiation of antiretroviral therapy (ART) regimens aimed at achieving greater concentrations within gut associated lymphoid tissue (GALT) impacts the level of mucosal immune reconstitution, inflammatory markers and the viral reservoir remains unknown. We included 12 HIV- controls and 32 ART-naïve HIV patients who were randomized to efavirenz, maraviroc or maraviroc+raltegravir, each with fixed-dose tenofovir disoproxil fumarate/emtricitabine. Rectal and duodenal biopsies were obtained at baseline and at 9 months of ART. We performed a comprehensive assay of T-cell subsets by flow cytometry, T-cell density in intestinal biopsies, plasma and tissue concentrations of antiretroviral drugs by high-performance liquid chromatography/mass spectroscopy, and plasma interleukin-6 (IL-6), lipoteichoic acid (LTA), soluble CD14 (sCD14) and zonulin-1 each measured by ELISA. Total cell-associated HIV DNA was measured in PBMC and rectal and duodenal mononuclear cells. Twenty-six HIV-infected patients completed the follow-up. In the duodenum, the quadruple regimen resulted in greater CD8(+) T-cell density decline, greater normalization of mucosal CCR5(+)CD4(+) T-cells and increase of the naïve/memory CD8(+) T-cell ratio, and a greater decline of sCD14 levels and duodenal HIV DNA levels (P = 0.004 and P = 0.067, respectively), with no changes in HIV RNA in plasma or tissue. Maraviroc showed the highest drug distribution to the gut tissue, and duodenal concentrations correlated well with other T-cell markers in duodenum, i.e., the CD4/CD8 ratio, %CD4(+) and %CD8(+) HLA-DR(+)CD38(+) T-cells. Maraviroc use elicited greater activation of the mucosal naïve CD8(+) T-cell subset, ameliorated the distribution of the CD8(+) T-cell maturational subsets and induced higher improvement of zonulin-1 levels. These data suggest that combined CCR5 and integrase inhibitor based combination therapy in ART treatment naïve patients might more effectively reconstitute duodenal immunity, decrease inflammatory markers and impact on HIV persistence by cell-dependent mechanisms, and show unique effects of MVC in duodenal immunity driven by higher drug tissue penetration and possibly by class-dependent effects. Public Library of Science 2016-01-21 /pmc/articles/PMC4721954/ /pubmed/26795282 http://dx.doi.org/10.1371/journal.ppat.1005381 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Serrano-Villar, Sergio Sainz, Talia Ma, Zhong-Min Utay, Netanya S. Wook-Chun, Tae Mann, Surinder Kashuba, Angela D. Siewe, Basile Albanese, Anthony Troia-Cancio, Paolo Sinclair, Elizabeth Somasunderam, Anoma Yotter, Tammy Deeks, Steven G. Landay, Alan Pollard, Richard B. Miller, Christopher J. Moreno, Santiago Asmuth, David M. Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial |
title | Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial |
title_full | Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial |
title_fullStr | Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial |
title_full_unstemmed | Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial |
title_short | Effects of Combined CCR5/Integrase Inhibitors-Based Regimen on Mucosal Immunity in HIV-Infected Patients Naïve to Antiretroviral Therapy: A Pilot Randomized Trial |
title_sort | effects of combined ccr5/integrase inhibitors-based regimen on mucosal immunity in hiv-infected patients naïve to antiretroviral therapy: a pilot randomized trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4721954/ https://www.ncbi.nlm.nih.gov/pubmed/26795282 http://dx.doi.org/10.1371/journal.ppat.1005381 |
work_keys_str_mv | AT serranovillarsergio effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT sainztalia effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT mazhongmin effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT utaynetanyas effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT wookchuntae effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT mannsurinder effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT kashubaangelad effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT siewebasile effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT albaneseanthony effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT troiacanciopaolo effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT sinclairelizabeth effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT somasunderamanoma effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT yottertammy effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT deekssteveng effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT landayalan effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT pollardrichardb effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT millerchristopherj effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT morenosantiago effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial AT asmuthdavidm effectsofcombinedccr5integraseinhibitorsbasedregimenonmucosalimmunityinhivinfectedpatientsnaivetoantiretroviraltherapyapilotrandomizedtrial |